These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 29270521

  • 1. Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4.
    Devuyst O, Chapman AB, Shoaf SE, Czerwiec FS, Blais JD.
    Kidney Int Rep; 2017 Nov; 2(6):1132-1140. PubMed ID: 29270521
    [Abstract] [Full Text] [Related]

  • 2. Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
    Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Lee J, Hoke ME, Estilo A, Sergeyeva O.
    Clin J Am Soc Nephrol; 2020 Dec 31; 16(1):48-58. PubMed ID: 33376102
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.
    Schaefer F, Mekahli D, Emma F, Gilbert RD, Bockenhauer D, Cadnapaphornchai MA, Shi L, Dandurand A, Sikes K, Shoaf SE.
    Eur J Pediatr; 2019 Jul 31; 178(7):1013-1021. PubMed ID: 31053954
    [Abstract] [Full Text] [Related]

  • 5. A Post Hoc Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials.
    Shoaf SE, Ouyang J, Sergeyeva O, Estilo A, Li H, Leung D.
    Clin J Am Soc Nephrol; 2020 May 07; 15(5):643-650. PubMed ID: 32241780
    [Abstract] [Full Text] [Related]

  • 6. Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?
    Liu F, Feng C, Shen H, Fu H, Mao J.
    Kidney Dis (Basel); 2021 Sep 07; 7(5):343-349. PubMed ID: 34604341
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
    Blair HA, Keating GM.
    Drugs; 2015 Oct 07; 75(15):1797-806. PubMed ID: 26407729
    [Abstract] [Full Text] [Related]

  • 10. Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials.
    Alpers DH, Lewis JH, Hunt CM, Freston JW, Torres VE, Li H, Wang W, Hoke ME, Roth SE, Westcott-Baker L, Estilo A.
    Am J Kidney Dis; 2023 Mar 07; 81(3):281-293.e1. PubMed ID: 36191725
    [Abstract] [Full Text] [Related]

  • 11. Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan.
    Muto S, Okada T, Shibasaki Y, Ibuki T, Horie S.
    Clin Exp Nephrol; 2021 Sep 07; 25(9):1003-1010. PubMed ID: 34089122
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Treatment persistence to tolvaptan in patients with autosomal dominant polycystic kidney disease: a secondary use of data analysis of patients in the IMADJIN® dataset.
    Thomas M, Gois PHF, Butcher BE, Ta MHT, Van Wyk GW.
    BMC Nephrol; 2021 Dec 02; 22(1):400. PubMed ID: 34856944
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD.
    Mallett AJ, Perrone RD, Rangan G, Hawley C, El-Damanawi R, Hiemstra TF, Arellano CT, Lee J, Torres VE.
    Kidney Int Rep; 2021 Apr 02; 6(4):1032-1040. PubMed ID: 33912753
    [Abstract] [Full Text] [Related]

  • 20. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
    Cornec-Le Gall E, Blais JD, Irazabal MV, Devuyst O, Gansevoort RT, Perrone RD, Chapman AB, Czerwiec FS, Ouyang J, Heyer CM, Senum SR, Le Meur Y, Torres VE, Harris PC.
    Nephrol Dial Transplant; 2018 Apr 01; 33(4):645-652. PubMed ID: 28992127
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.